Ensuring Optimal Integration of the GLP-1 Receptor Agonists: Review of the Latest Advances and Current Gaps in Care

Ensuring Optimal Integration of the GLP-1 Receptor Agonists: Review of the Latest Advances and Current Gaps in Care is organized by Rockpointe Corporation.

Release date: January 30, 2020
Expiration date: January 30, 2021

Accreditation:
CME Designation Statement
Boston University School of Medicine designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Designation Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables   the participant to earn up to 1.00 Medical Knowledge MOC points in the American Board of Internal   Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

American Academy of Family Physicians (AAFP) Credit
This Enduring Material activity, Ensuring Optimal Integration of the GLP-1 Receptor Agonists Review of the Latest   Advances and Current Gaps in Care , has been reviewed and is acceptable for up to 1.00 Prescribed credit(s) by   the American Academy of Family Physicians. AAFP certification begins 1/30/2020. Term of approval is for one   year from this date. Physicians should claim only the credit commensurate with the extent of their participation in the  activity.

Nursing Credit Designation
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hours. Designated for 0.6 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.

Overview:
Almost 10% of the US population has diabetes, and half are not achieving glycemic goals. GLP-1 receptor agonists (GLP-1 RAs) work by decreasing glucagon secretion in a glucose-dependent manner and by activating the GLP-1 receptor, increasing insulin release in the presence of elevated glucose concentrations. There are common misperceptions about injectable GLP-1 RAs, including an overestimation of patient fears of injection pain, that cause these agents to be under-prescribed.

Based on recent clinical-trial data, one GLP-1 RA is approved not only as an adjunct to diet and exercise to improve glycemic control in adults with T2DM, but also to reduce the risk of major cardiovascular events in adults with T2DM and established cardiovascular disease. GLP-1 RAs represent a unique approach to T2DM treatment, with potential benefits extending beyond glucose control and including positive effects on body weight, blood pressure, and beta-cell function. This activity, “Ensuring Optimal Integration of the GLP-1 Receptor Agonists,” will update primary care clinicians on the safety and efficacy data for approved GLP-RAs, review the most recent guideline and expert recommendations for their use, and suggest strategies to overcome barriers to their use in appropriate patients.

Educational Objectives:
This program is designed to address ACGME and NAM competencies, including delivering patient-centered care and practicing evidence-based medicine.
At the conclusion of this activity, participants should be able to:
• Evaluate the latest safety and efficacy data for each approved GLP-1 RA
• Incorporate GLP-1 RAs into effective T2DM treatment plans based on the latest expert and guideline recommendations
• Develop strategies to overcome misconceptions and barriers with the use of GLP-1 RAs in patients with T2DM